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Arbovirus control: what is the (real) stone in the way?
Dear Editor
Infections by arboviruses are a historic public health problem in tropical and 
subtropical countries and territories1. More recently, several factors, such as climate 
changes and globalization, have contributed to the increase of the distribution of 
arboviruses and (re-)emergence of some viral species in many areas, including 
temperate regions2,3. As a result, many universities, research centers and institutes 
around the world have the mosquito-borne viral diseases as major research object. 
Interestingly, the attention, investment and scientific rigor given to the subject 
sometimes have secondary importance and factors of non-scientific order contribute 
to widening the gap between research and population.
Regarding the reduction of mosquito vectors, various alternative measures, such 
as biocontrol strategies, have been strongly suggested to overcome the toxicity to 
non-target organisms and resistance mechanisms triggered by chemical insecticides. 
For example, larvicidal fish, such as Gambusia affinis and Poecilia reticulata, and 
copepods, such as Mesocyclops thermocyclopoides and M. longisetus, have been 
successfully used to control Aedes aegypti populations and decrease the number of 
Dengue virus (DENV) infections4. 
Despite the optimistic results of these and others related-interventions, it is 
necessary to evaluate their sustainability in different environments, long-term effects, 
influence on the ecological balance and on the interaction between target and non-
target species. The time and infrastructure required for the analysis, in addition to 
possibility of unsatisfactory results, require more cautious conclusions about the 
real contribution of vector control measures. Indeed, in this perspective, the relative 
distance between research and society is scientifically justified.
About the mass immunization, the development of some vaccine strategies is 
also hindered by scientific obstacles associated to molecular characteristics and 
pathogenesis of the target viral species. Multiple DENV serotypes and the possibility 
of antibody-dependent enhancement of infection have been an old problems for the 
development of a safe DENV vaccine. The fine balance between immunogenicity-
safety and the development of a safe vaccine for the fetus are the most important 
concerns for the chikungunya and Zika vaccines, respectively1. Historically, however, 
the gap between vaccine development and immunization action has been supported 
by other criteria, notably less scientific.
The yellow fever vaccine, for instance, although developed between 1930 and 
1940, has not yet been used as an effective disease prevention measure in many 
regions of South America and Africa. In recent literature, vaccine coverage for 
countries at risk for yellow fever ranged from 0% in parts of Central and Eastern 
Africa to 100% in part of the Amazonas State (Brazil)5. In Africa, risk areas for 
disease with lack of vaccination coverage included large part of Central and Eastern 
Africa and parts of Nigeria, Niger, Sierra Leone, Liberia and Guinea-Bissau5. In 
Brazil, only in 2018 an immunization plan for the whole country6 was established. In 
the same trend, the anti-dengue vaccine (CYD-DTV vaccine, ChimeriVax-Dengue/
Dengvaxia®), licensed since 2015 and currently approved in 20 countries, is not yet 
part of the immunization schedule of many countries where dengue fever is endemic7. 
In this context, in addition to investing in integrated vector management and/or 
vaccination strategies for arboviruses, it is also necessary to focus and discuss others 
factors, probably of economic and political origin, that hamper the implementation 
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of satisfactory scientifically measures. Otherwise, why 
investing funds and knowledge in laboratory practices 
if, ultimately, criteria that do not meet the scientific 
requirements seem to be the most important? In the broadest 
sense, following the verses of the Brazilian poet Carlos 
Drummond de Andrade (1928): “In the middle of the way 
had (has) a stone/Had (Has) a stone in the middle of the 
way” from the Portuguese “No meio do caminho tinha (tem) 
uma pedra/ Tinha (Tem) uma pedra no meio do caminho”; 
it is imperative to ask: what is the (real) stone between 
laboratory and social outcome?!
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